MMP1
ENSG00000196611
Target class
Enzyme
Chromosome
11
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- Yes
- Target name
- MMP1
- Gene name
- Matrix metallopeptidase 1
- Gene symbol
- MMP1
- Previous gene symbols
- CLG
- Protein name
- Interstitial collagenase (EC 3.4.24.7) (Fibroblast collagenase) (Matrix metalloproteinase-1) (MMP-1) [Cleaved into: 22 kDa interstitial collagenase; 27 kDa interstitial collagenase]
- Gene biotype
- Protein coding
- Gene family
- Receptor ligands|M10 matrix metallopeptidases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 6
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 51.85
- Tissue specificity (Gini)
- 0.928
- Tissue specificity (tau)
- 0.991
- KEGG gene identifiers
- hsa:4312
- Protein interaction confidence
- 0.804591
- Protein interaction partners
- 44
- R-HSA-1442490
- R-HSA-1474228
- R-HSA-1592389
- R-HSA-210991
- R-HSA-381426
- R-HSA-6785807
- End position
- 102798160
- Start position
- 102789401
- Chromosome
- 11
- Strand
- Reverse
- Secreted, extracellular space, extracellular matrix .
- Vesicles
Publication evidence
- PubMed 2167156
- Tissue specificity (tau)
- 0.991077
- Expression inequality (Gini)
- 0.92813
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 51.85
- Stomach
- 10.15
- Spleen
- 3
- Small Intestine - Terminal Ileum
- 2.38
- Lung
- 2.29
Expression in transcripts per million
- Cells - Cultured fibroblasts51.85
- Stomach10.15
- Spleen3
- Small Intestine - Terminal Ileum2.38
- Lung2.29
- Kidney - Medulla1.46
- Colon - Transverse0.81
- Minor Salivary Gland0.67
- Kidney - Cortex0.52
- Bladder0.48
- Testis0.32
- Pancreas0.29
- Esophagus - Mucosa0.16
- Adipose - Subcutaneous0.16
- Artery - Aorta0.14
- Thyroid0.14
- Artery - Coronary0.13
- Prostate0.13
- Skin - Sun Exposed (Lower leg)0.12
- Vagina0.1
- Adipose - Visceral (Omentum)0.09
- Breast - Mammary Tissue0.09
- Fallopian Tube0.08
- Whole Blood0.08
- Skin - Not Sun Exposed (Suprapubic)0.08
And 29 more, listed on the interactive page.
- GO:0006508
- GO:0022617
- GO:0030574
- GO:0031334
- GO:0071492
Cellular components
- GO:0005576
- GO:0004175
- GO:0004222
- GO:0004252
- GO:0008233
- GO:0008270
regulation of transcription factor activity
Studies
- cell-based: LTEA_HepaRG_MMP1is one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Fibrosis.
Biological samples
- HepaRG, cell line
Evidence sourceregulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hMMP1, is one of one assay component(s) measured or calculated from the NVS_ENZ_hMMP1 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.
Biological samples
- cell-free
Evidence sourceregulation of gene expression
- cell-based: BSK_BE3C_MMP1, is one of 11 assay component(s) measured or calculated from the BSK_BE3C assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
- cell-based: BSK_hDFCGF_MMP1, is one of 12 assay component(s) measured or calculated from the BSK_hDFCGF assay. It is designed to make measurements of enzyme-linked immunosorbent assay, a form of binding reporter, as detected with fluorescence intensity signals by Enzyme-linked immunosorbent assay technology.
- bronchial epithelial cells, primary cell
- foreskin fibroblast, primary cell
Evidence source
Related records
Trials (340)
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
- A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka
- A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
- A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease
- A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea
- A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
- A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
- A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules
- A Novel Combination Oral Agent to Treat Acne Vulgaris
- A Phase II Study of Doxycycline in Relapsed NHL
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
- A Pilot Study of Inflammatory Markers in Alzheimer's Disease
- A Randomized Controlled Trial of Doxycycline Post Exposure Prophylaxis to Prevent Incident Bacterial STIs Among Women in the United States
- A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions
- A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
- A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations
- A Study of ALTY-0501 for the Treatment of Dry Eye Administered 4 Times a Day for a 56 Day Period
Drugs (6)
- Doxycycline Matrix metalloproteinase-1 inhibitor
- Doxycycline anhydrous Matrix metalloproteinase-1 inhibitor
- Doxycycline calcium Matrix metalloproteinase-1 inhibitor
- Doxycycline hyclate Matrix metalloproteinase-1 inhibitor
- Marimastat Matrix metalloproteinase-1 inhibitor
- Rebimastat Matrix metalloproteinase-1 inhibitor